{"id":"NCT01594749","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","officialTitle":"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-24","primaryCompletion":"2014-11-03","completion":"2014-11-03","firstPosted":"2012-05-09","resultsPosted":"2015-09-25","lastUpdate":"2018-09-04"},"enrollment":1015,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Chemotherapy-Induced Nausea and Vomiting (CINV)"],"interventions":[{"type":"DRUG","name":"Fosaprepitant dimeglumine","otherNames":["EMEND for Injection","MK-0517"]},{"type":"DRUG","name":"Fosaprepitant Placebo","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Decadron"]},{"type":"DRUG","name":"Ondansetron","otherNames":["Zofran"]},{"type":"DRUG","name":"Dexamethasone Placebo","otherNames":[]},{"type":"DRUG","name":"Ondansetron Placebo","otherNames":[]},{"type":"DRUG","name":"Rescue Therapy","otherNames":[]}],"arms":[{"label":"Fosaprepitant Regimen","type":"EXPERIMENTAL"},{"label":"Control Regimen","type":"ACTIVE_COMPARATOR"}],"summary":"This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 antagonist and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).","primaryOutcome":{"measure":"Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC)","timeFrame":"25 to 120 hours after initiation of MEC","effectByArm":[{"arm":"Fosaprepitant Regimen","deltaMin":78.9,"sd":null},{"arm":"Control Regimen","deltaMin":68.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26449391","32988373","29808377"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":504},"commonTop":["Fatigue","Diarrhoea","Constipation","Neutropenia","Headache"]}}